nirmatrelvir 150 mg Tablet, Film Coated, 235,000-count — NDC 53869-2085-9 (Billing 53869-2085-09)
This is a package of 235,000 tablets of nirmatrelvir 150 mg Tablet, Film Coated from Pfizer Manufacturing Deutschland GmbH, first listed with the FDA Nov 2021 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 53869-2085-9 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 53869 labeler · 2085 product · 9 package
- Package marketed since
- Nov 26, 2021
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 5386920859 0
- FDA record last changed
- Nov 12, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
This is a film-coated tablet containing 150 mg of nirmatrelvir, listed as a drug for further processing. Nirmatrelvir is an antiviral medication that functions as a protease inhibitor, typically used to reduce viral replication in certain viral infections. This product form is intended for pharmaceutical manufacturing or processing rather than direct consumer use.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 53869-2085-09 You're viewing this Main listing | 1 BAG in 1 BOX / 235000 TABLET, FILM COATED in 1 BAG | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| nirmatrelvir 150 mg 63285-0892-00 | Patheon, | 12945 tablets | — | — | FDA listed | — |
| nirmatrelvir 150 mgthis 53869-2085-09 | Pfizer | 235000 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 20, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Pfizer Manufacturing Deutschland GmbH labeler code 53869
- lorlatinib 100 mg Tablet, Film Coated NDC 53869-1043-1
- abrocitinib 50 mg Tablet, Film Coated NDC 53869-1235-8
- abrocitinib 100 mg Tablet, Film Coated NDC 53869-1335-8
- abrocitinib 200 mg Tablet, Film Coated NDC 53869-1435-8
- Pregabalin 165 mg Tablet, Film Coated, Extended Release NDC 53869-1473-1
- doxazosin 2 mg Tablet NDC 53869-2076-1
- Crizotinib 250 mg Capsule NDC 53869-2230-1
- Crizotinib 200 mg Capsule NDC 53869-2231-1
- Pregabalin 330 mg Tablet, Film Coated, Extended Release NDC 53869-2347-1
- doxazosin mesylate 1 mg Tablet NDC 53869-2710-1
- doxazosin mesylate 2 mg Tablet NDC 53869-2720-1
- doxazosin mesylate 4 mg Tablet NDC 53869-2740-1
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Pfizer Manufacturing Deutschland GmbH supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |